Nuvation Bio Inc.
For the period ended Aug 6, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 6, 2026 · Filed Aug 6, 2026
NUVB$4.16-0.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Indication
Indication
IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+non-small cell lung cancer (NSCLC).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.